This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Pennant Group, Inc. (PNTG) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
The Pennant Group (PNTG) delivered earnings and revenue surprises of +3.85% and +3.16%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
DaVita HealthCare (DVA) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of +9.26% and +1.31%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Quest Diagnostics, Encompass Health, DaVita and The Pennant
by Zacks Equity Research
DGX, EHC, DVA, and PNTG are riding the outpatient healthcare shift as tech, AI, and aging demand reshape the care landscape.
4 Stocks to Watch in a Rapidly Shifting Outpatient Home Health Space
by Debanjana Dey
An aging global population and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, EHC, DVA and PNTG are well-poised to gain.
Encompass Health to Expand Florida Presence With New 50-bed Facility
by Zacks Equity Research
EHC already boasts a massive footprint of 167 hospitals in 38 states and Puerto Rico.
The Pennant Group (PNTG) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for The Pennant Group (PNTG) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
The Pennant Group, Inc. (PNTG) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
The Pennant Group (PNTG) delivered earnings and revenue surprises of 22.73% and 3.68%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Can The Pennant Group (PNTG) Climb 28.58% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 28.6% in The Pennant Group (PNTG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Are Options Traders Betting on a Big Move in The Pennant Group (PNTG) Stock?
by Zacks Equity Research
Investors need to pay close attention to The Pennant Group (PNTG) stock based on the movements in the options market lately.
AVAH Surges 45% in Five Days: How to Play the Stock After Earnings?
by Harshit Gupta
AVAH trades at a discount despite growth in payor deals & services. With solid fundamentals amid labor shortages, is it a buy or hold after earnings?
The Pennant Group, Inc. (PNTG) Q4 Earnings Miss Estimates
by Zacks Equity Research
The Pennant Group (PNTG) delivered earnings and revenue surprises of -4% and 1.12%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Chemed (CHE) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Chemed (CHE) delivered earnings and revenue surprises of 0.59% and 1.78%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Stay Ahead of the Game With The Pennant Group (PNTG) Q4 Earnings: Wall Street's Insights on Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for The Pennant Group (PNTG), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
Addus HomeCare (ADUS) Q4 Earnings Match Estimates
by Zacks Equity Research
Addus HomeCare (ADUS) delivered earnings and revenue surprises of 0% and 1.71%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
DGX vs. PNTG: Which Stock Is the Better Value Option?
by Zacks Equity Research
DGX vs. PNTG: Which Stock Is the Better Value Option?
The Pennant Group (PNTG) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for The Pennant Group (PNTG) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
The Pennant Group, Inc. (PNTG) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
The Pennant Group (PNTG) delivered earnings and revenue surprises of 13.04% and 3.49%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Encompass Health (EHC) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Encompass Health (EHC) delivered earnings and revenue surprises of 9.57% and 1.73%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
DGX or PNTG: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DGX vs. PNTG: Which Stock Is the Better Value Option?
Acadia Healthcare Ventures in South Carolina With Three Buyouts
by Zacks Equity Research
ACHC expands its CTC network by acquiring three opioid treatment program clinics in South Carolina.
Can DaVita Stock Continue Its Bull Run After Doubling in a Year?
by Indrajit Bandyopadhyay
DVA stock has the potential to continue its uptrend on the back of better revenues per treatment as well as growth of the overall dialysis market.
Here's Why You Should Add Elevance Health Stock to Your Portfolio
by Zacks Equity Research
ELV benefits from an increase in employer group fee-based memberships, partially offsetting the impact of Medicaid memberships.
Compelling Reasons to Hold on to Encompass Health Stock Right Now
by Zacks Equity Research
EHC remains well-poised for growth on the back of improved revenues, an extensive rehabilitation hospital network and sufficient cash-generating abilities.
Here is Why Growth Investors Should Buy The Pennant Group (PNTG) Now
by Zacks Equity Research
The Pennant Group (PNTG) possesses solid growth attributes, which could help it handily outperform the market.
DaVita Stock Rallies 17% in 3 Months: Is it Still Worth Buying?
by Indrajit Bandyopadhyay
DVA stock has the potential to continue its uptrend on the back of better revenues per treatment as well as growth of the overall dialysis market.